Specialist

Q1 slowdown

Value currently underperforming

High conviction portfolio

Tech not immune from growth concerns

Two hard years for African equities

Biotech has fallen

Tom Delic, assistant fund manager at Seneca Investment Managers explores the demographic trends - from opportunities in tech to wealth management - that are available for investors to take advantage of

Just over a month ago, volatility, as measured by the VIX index was around 26%, the highest reading since the Chinese slowdown scare of last August. The FTSE 100 was plunging, reaching its nadir of 5,500 in the morning of 11 February.

Growth in derivative-based defined return investments

The biotechnology sector has been hit particularly hard by the risk-averse sentiment sweeping through global stock markets and after reaching a high in July 2015, the Nasdaq Biotechnology index shed about one-third of its value.